A retrospective review of treatment and response of high-risk mast cell tumours in dogs

This retrospective case series evaluates survival outcome of 94 dogs with high metastatic risk mast cell tumours (MCT). Patients were treated with a cytotoxic chemotherapy protocol or the tyrosine kinase inhibitor masitinib, in the presence of gross disease or as an adjunct to surgical resection of...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary & comparative oncology 2016-12, Vol.14 (4), p.361-370
Main Authors: Miller, R. L., Van Lelyveld, S., Warland, J., Dobson, J. M., Foale, R. D.
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
canine
chemotherapy
Chemotherapy, Adjuvant - veterinary
Dog Diseases - drug therapy
Dog Diseases - mortality
Dog Diseases - surgery
Dogs
masitinib
Mastocytoma - drug therapy
Mastocytoma - mortality
Mastocytoma - surgery
Mastocytoma - veterinary
metastasis
Neoplasm Grading
Protein Kinase Inhibitors - therapeutic use
Retrospective Studies
Risk Factors
surgery
Survival Analysis
Thiazoles - therapeutic use
Treatment Outcome
tyrosine kinase
vinblastine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This retrospective case series evaluates survival outcome of 94 dogs with high metastatic risk mast cell tumours (MCT). Patients were treated with a cytotoxic chemotherapy protocol or the tyrosine kinase inhibitor masitinib, in the presence of gross disease or as an adjunct to surgical resection of the primary tumour. In patients presenting with metastatic disease, surgical resection of the primary tumour with adjunctive therapy with any chemotherapy incurred a significant survival advantage [median survival time (MST): 278 days] compared to patients receiving chemotherapy without surgical excision of the primary tumour (MST: 91 days, P < 0.0001). Patients with a surgically excised Patnaik grade II tumour and high Ki‐67 in the absence of metastatic disease treated with vinblastine and prednisolone showed a significantly longer survival (MST: 1946 days) than those treated with masitinib (MST: 369 days, P = 0.0037). Further prospective case‐controlled clinical trials of high‐risk MCTs are required to make precise evidence‐based treatment decisions for individual patients.
ISSN:1476-5810
1476-5829
DOI:10.1111/vco.12116